WFH NETWORK

WFH Humanitarian Aid Program


The lack of access to care and treatment in developing countries is an urgent and important public health challenge.

The WFH is leading the effort to change this lack of access by providing consistent and predictable treatment for all people with inherited bleeding disorders.


LEARN MORE

DONATE NOW

CONTRIBUTORS

WFH HUMANITARIAN AID PROGRAM
Visionary Contributors Contributors
Sanofi Genzyme CSL Behring
Sobi GC Pharma
  Grifols
  F. Hoffmann-La Roche Ltd.


The visionary contribution from Sanofi Genzyme and Sobi to the WFH Humanitarian Aid Program translates into 500 million IUs over five years (2015-2020). Sanofi Genzyme and Sobi also make ongoing substantial financial contributions to support the logistics of product delivery and training of providers and patients in humanitarian aid countries. Furthermore, the eight-year commitment (2014-2021) from Grifols totaling 200 million IUs, along with a ten-year commitment (2009-2018) from CSL Behring for a total of 22 million IUs, the three-year agreement (2017-2019) with GC Pharma for 6 million IUs, and Roche, as a new donor, with a 5 year commitment (2019-2024) will provide products for prophylactic treatment, allowing for a more predictable and sustainable flow of humanitarian aid donations to the global community.


Articles


WFH Humanitarian Aid Program: Impact Report 2018

 

The lack of access to care and treatment for people affected with a bleeding disorder in developing countries is an urgent and important public health challenge. Through its Humanitarian Aid Program, the WFH is leading the effort to change this situation in developing countries by providing consistent, predictable, and free access to medical treatment.

“WFH Humanitarian Aid Program: Impact Report 2018” assesses the effect on the ground of the WFH Humanitarian Aid Program. Through key performance indicators, case studies and testimonials, the report presents the real-life effect of the program on our targeted populations while analyzing the progress made in terms of sustainable care on our path to Treatment for All.

Click here to download >


Haemophilia Journal article details WFH Humanitarian Aid Program achievements

In “First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries” (G. F. Pierce et al, Haemophilia. 2018;24:229-235) readers have the chance to learn about the achievements of the WFH Humanitarian Aid Program in 2016—a year after the program’s scope was expanded. Along with contributions by WFH staff and volunteers, Glenn Pierce, MD, PhD, WFH Vice-President Medical, explores the situation in recipient countries before the expansion of this program and highlights how these countries could now respond to the treatment needs more effectively due to the increased predictability of donations. To read the full article, please click here.

Latest news on the WFH Humanitarian Aid Program  

The WFH talks to members of our global bleeding disorders community about the impact of, and the need for, the Humanitarian Aid Program during the 2016 World Congress. 


Charitable solicitations for the common purposes of WFH and WFH USA within the U.S. are conducted through WFH USA, a 501(c)3 affiliated entity.